(MedPage Today) — SAN DIEGO — Fremanezumab (Ajovy) cut monthly migraine days in children and adolescents with episodic migraine, according to the SPACE trial.
The phase III study showed a reduction in monthly migraine days in patients (mean…
Source link
Anti-CGRP Drug Reduces Episodic Migraine in Kids
